Skip to main content

Table 1 Pretreatment patient characteristics

From: Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study

   All patients Palliative Chemotherapy No Chemotherapy p value
   n = 91 n = 40 n = 51  
Age (years) Median (range) 58 (25 - 82) 55 (25 - 74) 59 (34 - 82) 0.03
Gender Male 67 (73.6%) 31 (77.5%) 36 (70.6%) 0.46
ECOG PS 0/1 54 (59.3%) 32 (80.0%) 22 (43.1%) <0.01
  2/3 33 (36.3%) 8 (20.0%) 25 (49.0%)  
  NA 4 (4.4%) 0 (0.0%) 4 (7.8%)  
Primary cancer site Duodenum 71 (78.0%) 28 (70.0%) 43 (84.3%) 0.10
  Jejunoileum 20 (22.0%) 12 (30.0%) 8 (15.7%)  
Histology WD/MD 44 (48.4%) 18 (45.0%) 26 (51.0%) 0.57
  Undifferentiated 38 (41.8%) 19 (47.5%) 19 (37.3%)  
  Undetermined 9 (9.8%) 3 (7.5%) 6 (11.8%)  
Status Recurrent 17 (18.7%) 11 (27.5%) 6 (11.8%) 0.15
  Locally advanced 4 (4.4%) 2 (5.0%) 2 (3.9%)  
  Metastatic 70 (76.9%) 27 (67.5%) 43 (84.3%)  
Primary tumor Resected 29 (31.9%) 19 (47.5%) 10 (19.6%) <0.01
  Still present 62 (68.1%) 21 (52.5%) 41 (80.4%)  
Number of metastasis 0 4 (4.4%) 2 (5.0%) 2 (3.9%) 0.62
  1 50 (54.9%) 24 (60.0%) 26 (51.0%)  
  ≥2 37 (40.7%) 14 (35.0%) 23 (45.1%)  
Liver metastasis Yes 39 (42.9%) 14 (35.0%) 25 (49.0%) 0.18
Peritoneal metastasis Yes 42 (46.2%) 19 (47.5%) 23 (45.1%) 0.82
IALN metastasis Yes 41 (45.1%) 13 (32.5%) 28 (54.9%) 0.03
Lung metastasis Yes 6 (6.6%) 2 (5.0%) 4 (7.8%) 0.59
Bone metastasis Yes 3 (3.3%) 2 (5.0%) 1 (2.0%) 0.42
Treatment interval 1989-1999 25 (27.5%) 10 (25.0%) 15 (29.4%) 0.64
  2000-2009 66 (72.5%) 30 (75.0%) 36 (70.6%)  
  1. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; NA, not available; WD, well-differentiated; MD, moderately differentiated; IALN, intra-abdominal lymph node.